A multicenter, phase II, double blind, randomized, parallel group, placebo-controlled study to evaluate the hemodynamic responses to intravenous RLX030 infusion in subjects with acute heart failure.

Trial Profile

A multicenter, phase II, double blind, randomized, parallel group, placebo-controlled study to evaluate the hemodynamic responses to intravenous RLX030 infusion in subjects with acute heart failure.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Acute heart failure
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Novartis; Novartis Pharma A.G.
  • Most Recent Events

    • 18 Nov 2013 Results published in the European Heart Journal.
    • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Oct 2012 Planned end date changed from 1 Oct 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top